Treatment optimization in patients with erectile dysfunction


Cite item

Full Text

Open Access Open Access
Restricted Access Access granted
Restricted Access Subscription or Fee Access

Abstract

Erectile dysfunction (ED) is one of the most urgent problems of modern urology, significantly affecting quality of life of male population worldwide. According to European Association of Urology ED is defined as the persistent inability to attain and maintain an erection sufficient to permit satisfactory sexual performance. Premature ejaculation (PE) is also a significant medical and social issue as it seriously affects the quality of life, especially in the presence of more or less severe ED. The aim of this study was to determine the clinical efficacy and safety of combination therapy of phosphodiesterase type 5 inhibitors and dietary supplements NeyroDoz in patients with ED and PE. The study results demonstrate the effectiveness and good compatibility of phosphodiesterase type 5 inhibitors and dietary supplements NeyroDoz as a combination therapy in patients with ED and PE. Dietary supplement, having a good tolerance, reduced psychosomatic symptom and significantly increased duration of intercourse, thus significantly improving the quality of patients sexual life. The feasibility to prolong the effect of the therapy by the individual adjustment of NeyroDoz dosing mode after a 60-day treatment course offers new opportunities for personalized medicine, and the dietary supplement may be recommended as a complementary preparation to provide an adequate sexual functioning.

About the authors

D Ju Pushkar

A.I. Evdokimov Moscow State Medical and Dental Universit

A.I. Evdokimov Moscow State Medical and Dental Universit

K B Kolontarev

A.I. Evdokimov Moscow State Medical and Dental Universit

A.I. Evdokimov Moscow State Medical and Dental Universit

References

  1. Gratzke C., Angulo J., Chitaley K., Dai Y.T., Kim N.N., Paick J.S., Simonsen U., Uckert S., Wespes E., Andersson K.E., Lue T.F., Stief C.G. Anatomy, physiology, and pathophysiology of erectile dysfunction. J. Sex. Med. 2010;7(1 Pt2):445-475. 2.
  2. EAU Guidelines. Male sexual dysfunction. 2015.
  3. Kinsey A.C., et al. Age and sexual outlet. In: Kinsey A.C., Pomeroy W.B.. Martin C.E. Sexual Behavior in the Human Male. Philadelphia: WB Sauders; 1948. P. 218.
  4. Feldman H.A., Goldstein I., Hatzichristou D.G., Krane R.J., McKinlay J.B. Impotence and its medical and psychosocial correlates: results of the Massachusetts male aging study. J. Urol. 1994;151:54.
  5. Пушкарь Д.Ю., Камалов А.А., Аль-Шукри С.Х., Еркович А.А., Коган М.И., Павлов В.Н., Журавлев В.Н., Берников А.Н. Эпидемиологическое исследование распространенности эректильной дисфункции в Российской Федерации. Уральский медицинский журнал. 2012;3:75-79.
  6. Nehra A. Erectile dysfunction and cardiovascular disease: efficacy and safety of phosphodiesterase type 5 inhibitors in men with both conditions. Mayo Clin. Proc. 2009;84(2):139-148. 7.
  7. Diagnostic and Statistical Manual of Mental Disorders. 4th edn. Revision. American Psychiatric Publishing Inc: Washington, DC; 2000. 8.
  8. World Health Organization, International Classification of Diseases and Related Health Problems. 10th edn. Geneva; 1994.
  9. McMahon C.G., Abdo C., Incrocci L., Perelman M., Rowland D., Waldinger M., Xin Z.C. Disorders of orgasm and ejaculation in men. J. Sex. Med. 2004;1(1):58-65. 10.
  10. SerefogluE.C.,McMahonC.G., WaldingerM.D.,Althof S.E.,Shindel A., Adaikan G.,Becher E.F., Dean J., Giuliano F., Hellstrom W.J., GiraldiA., Glina S., Incrocci L., Jannini E., McCabe M., Parish S., Rowland D., Segraves R.T., Sharlip I., Torres L.O. An evidence-based unified definition of lifelong and acquired premature ejaculation: report of the second International Society for Sexual Medicine Ad Hoc Committee for the Definition of Premature Ejaculation. J. Sex. Med. 2014;11(6):1423-1441.
  11. Калинченко С.Ю., Роживанов Р.В. Современные подходы к изучению преждевременной эякуляции. Сексология. 2003;11:2-7.
  12. Pryor J.L., Althof S.E., Steidle C., Rosen R.C., Hellstrom W.J., Shabsigh R., Miloslavsky M., Kell S.; Dapoxetine Study Group. Efficacy and tolerability of dapoxetine in the treatment of premature ejaculation. J. Urol. 2005;173(4):201.
  13. Hatzimouratidis K., AmarE., Eardley I., Giuliano F., Hatzichristou D., Montorsi F., Vardi Y., Wespes E.; European Association of Urology. Guidelines on Male Sexual Dysfunction: Erectile Dysfunction and Premature Ejaculation. Eur. Urol. 2010;57(5):804-814.
  14. Щербаков Д.В. Диагностика и лечение преждевременной эякуляции, сочетающейся с эректильной дисфункцией. Дисс. канд. мед. наук. М., 2011.
  15. Камалов А.А., Абоян И.А., Ситдыкова М.Э., Цуканов А.Ю., Теодорович О.В., Медведев В.Л., Комяков Б.К., Журавлев В.Н., Новиков А.И., Еркович А.А., Охоботов Д.А., Карпов В.К., Зубков А.Ю. Терапия ускоренного семяизвержения биологически актиной добавкой к пище НейроДоз: результаты мультицентрового клинического нерандомизированного исследования. Урология. 2013;15:1-5. 16.
  16. Тер Авнесов Г.В. Плацебо контролируемое исследование эффективности препарата НейроДоз у мужчин с преждевременной эякуляцией. 2011. <http://agesta.ru/nd.pdf>
  17. Кузьменко А.В., Кузьменко В.В., Гяургиев Т.А., Строева Д.Е. Хронобиологические аспекты применения препарата «Нейродоз» у больных с эректильной дисфункцией. Урология. 2014;5:90-94.
  18. Виноградов И.В., Коршунов М.Н., Коршунова Е.С. Возможности применения биокомплекса Нейродоз для лечения больных вторичной преждевременной эякуляцией на фоне хронического простатита. Андрология и генитальная хирургия. 2015;2:56-60.

Supplementary files

Supplementary Files
Action
1. JATS XML
Download

This website uses cookies

You consent to our cookies if you continue to use our website.

About Cookies